1. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
   Emma Eriksson et al, 2017, Clinical Cancer Research CrossRef
2. Obtaining Gene-Modified HLA-E-Expressing Feeder Cells for Stimulation of Natural Killer Cells
   Nadezhda A. Alekseeva et al, 2024, Pharmaceutics CrossRef
3. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency
   Mohammed F. Alosaimi et al, 2019, Journal of Allergy and Clinical Immunology CrossRef
4. Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation
   Stefan O. Ciurea et al, 2017, Blood CrossRef
5. An acetylated derivative of vitexin halts MDA-MB-231 cellular progression and improves its immunogenic profile through tuning miR- 20a-MICA/B axis
   Aya R. Awad et al, 2021, Natural Product Research CrossRef
6. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
   Ignacio Melero et al, 2023, Cancer Discovery CrossRef
7. Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics
   Kassandra M. Coyle et al, 2023, Cancers CrossRef
8. Advances in oncolytic adenovirus therapy for pancreatic cancer
   Callum Baird Nattress et al, 2018, Cancer Letters CrossRef
9. Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
   Lucile Dumolard et al, 2023, Frontiers in Immunology CrossRef
10. Breaking down barriers: The potential of smarter CAR‐engineered NK cells against solid tumors
    Muhammad B. Khawar et al, 2023, Journal of Cellular Biochemistry CrossRef
11. Challenges of NK cell-based immunotherapy in the new era
    Fang Fang et al, 2018, Frontiers of Medicine CrossRef
12. Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays
    Amir Seyfoori et al, 2021, Drug Discovery Today CrossRef
13. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
    Dean A. Lee, 2019, Immunological Reviews CrossRef
14. Development of an antibody-ligand fusion protein scFvCD16A-sc4-1BBL in Komagataella phaffii with stimulatory activity for Natural Killer cells
    Yangyang Li et al, 2023, Microbial Cell Factories CrossRef
15. CD40 stimulation via CD40 ligand enhances adenovirus‐mediated tumour immunogenicity including ‘find‐me’, ‘eat‐me’, and ‘kill‐me’ signalling
    Sedigheh Naseri et al, 2024, Journal of Cellular and Molecular Medicine CrossRef
16. CAR NK Cells: The Future Is Now
    Martin J. Raftery et al, 2023, Annual Review of Cancer Biology CrossRef
17. NK cell-based immunotherapy for cancer
    Fang Fang et al, 2017, Seminars in Immunology CrossRef
18. Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate
    Christopher D. L. Johnson et al, 2022, Frontiers in Immunology CrossRef
19. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
    Margaret G. Lamb et al, 2021, Stem Cell Research & Therapy CrossRef
20. New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology
    Mehmet Gunduz et al, 2021, Biomedicines CrossRef
21. Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy
    Jian Gao et al, 2020, Cancers CrossRef
22. A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma
    Juliane Wagner et al, 2017, Frontiers in Immunology CrossRef
23. Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells
    Jinho Kim et al, 2023, Scientific Reports CrossRef